RT Journal Article SR Electronic T1 In Vivo Models for the Performance and Safety of BAT-90, a Novel 90-Yttrium-based Internal Radiotherapy Platform JF In Vivo JO In Vivo FD International Institute of Anticancer Research SP 2052 OP 2060 DO 10.21873/invivo.12931 VO 36 IS 5 A1 ANTONINO AMATO A1 GORDON MCVIE A1 GIOVANNI PAGANELLI A1 PIER LUIGI CARRIERO A1 ROBERTO CIANNI A1 GIUSEPPE MARIA ETTORRE YR 2022 UL http://iv.iiarjournals.org/content/36/5/2052.abstract AB Background/Aim: BAT-90 is an innovative active implantable device designed for the irradiation of unresectable tumors (e.g., liver cancer) or surgical tumor beds, based on the combination of Yttrium-90 beta-emitting microspheres and a tissue adhesive hydrogel, currently used in cardio-vascular surgery. The rationale behind BAT-90 is to localize the Yttrium-90 activity on the administration site, while minimizing its body dispersion. Materials and Methods: The effective induction of necrosis in the target injection area was tested in a pig liver model, whereas the safety of BAT-90 was assessed and demonstrated in biocompatibility tests for acute systemic toxicity, intracutaneous reactivity, delayed hypersensitivity and subcutaneous implantation. Results: BAT-90 administration induced necrosis into the target site, while the safety experiments in the treated animals highlighted results very similar to the controls. Conclusion: BAT-90 could be considered as a safe and innovative treatment option for inoperable solid tumors of the liver.